Hsbc Holdings PLC Acquires 527,506 Shares of Kenvue Inc. (NYSE:KVUE)

Hsbc Holdings PLC boosted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 18.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,369,706 shares of the company's stock after acquiring an additional 527,506 shares during the quarter. Hsbc Holdings PLC owned 0.18% of Kenvue worth $71,853,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. OneDigital Investment Advisors LLC raised its stake in shares of Kenvue by 3.8% during the fourth quarter. OneDigital Investment Advisors LLC now owns 19,252 shares of the company's stock valued at $411,000 after acquiring an additional 699 shares during the last quarter. Van Lanschot Kempen Investment Management N.V. raised its position in Kenvue by 1.5% during the 4th quarter. Van Lanschot Kempen Investment Management N.V. now owns 1,353,596 shares of the company's stock worth $28,899,000 after purchasing an additional 20,614 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Kenvue by 53.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 149,644 shares of the company's stock worth $3,195,000 after buying an additional 51,903 shares during the period. Transatlantique Private Wealth LLC grew its position in shares of Kenvue by 5.7% in the 4th quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company's stock valued at $228,000 after buying an additional 580 shares during the last quarter. Finally, Trajan Wealth LLC grew its position in shares of Kenvue by 10.7% in the 4th quarter. Trajan Wealth LLC now owns 204,966 shares of the company's stock valued at $4,376,000 after buying an additional 19,797 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 0.4 %

NYSE KVUE traded up $0.09 on Wednesday, reaching $23.47. The company had a trading volume of 1,976,827 shares, compared to its average volume of 17,040,509. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company's fifty day moving average is $23.06 and its 200 day moving average is $22.46. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a market capitalization of $45.02 billion, a P/E ratio of 44.25, a P/E/G ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.49%. Kenvue's payout ratio is presently 154.72%.

Analysts Set New Price Targets

Several brokerages recently commented on KVUE. Citigroup upped their target price on Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a report on Monday, April 14th. Barclays decreased their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, April 14th. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Redburn Atlantic started coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Finally, Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and an average target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.